Familial dysautonomia (FD), also known as hereditary sensory and autonomic neuropathy III (HSAN-III; Riley-Day Syndrome), is a fatal autosomal recessive disease characterized by the degeneration of sensory and autonomic neurons[@R8],[@R10]. The pathogenesis of the disease and its specificity to the peripheral nervous system are poorly understood. Most FD patients carry a point mutation in the I-κ-B kinase complex-associated protein (*IKBKAP*) gene resulting in a tissue specific splicing defect with various levels of exon 20 skipping and reduced levels of normal IKAP protein[@R8],[@R11]. Reduced IKAP protein levels are associated with a defect in cell motility[@R9]. However, it is unclear whether decreased cell motility is functionally related to the specific peripheral neuron pathology observed in FD. Based on the splicing defect, *in vitro* drug screens have been performed in patient lymphoblast cell lines to identify compounds that improve normal *IKBKAP* splicing and increase IKAP protein levels[@R12]. However, lack of access to tissues affected by FD, such as neural crest precursors and peripheral neurons, has hampered functional validation of candidate drugs and a systematic analysis of disease pathogenesis. Here we demonstrate the potential of human iPSC technology to model FD pathogenesis and treatment ([Suppl. Fig. 1](#SD1){ref-type="supplementary-material"}).

We obtained fibroblasts from a 10 year old female FD patient and established two independent clones of FD-iPSCs (FD\#4, FD\#22) following transduction with lentiviral vectors encoding for OCT4, SOX2, KLF4 and cMYC ([Fig. 1a-c](#F1){ref-type="fig"}). Additional iPSCs clones were derived from two other FD patients (16 year old male and 12 year old female FD patient) and from non-affected control fibroblasts using the same procedure. The vector system used for iPSC generation allowed convenient monitoring of transgene expression by individual fluorescence tags via P2A technology[@R13]. All FD- and control iPSCs used in this study showed silencing of the four transgenes, exhibited characteristic human ES cell morphology, expressed pluripotency markers including Nanog, SSEA3, SSEA4, Tra-1-81 and had a normal karyotype ([Fig. 1b-f](#F1){ref-type="fig"}; Suppl. Fig. [2](#SD1){ref-type="supplementary-material"}-[3](#SD1){ref-type="supplementary-material"}). Pluripotent properties of FD-iPSCs were further assessed by monitoring methylation status of the Nanog promoter ([Fig. 1g](#F1){ref-type="fig"}), by global transcriptome analysis in comparison to FD-fibroblasts, hESCs (line H9) and control-iPSC lines ([Fig. 1h](#F1){ref-type="fig"}, [Suppl. Fig. 3](#SD1){ref-type="supplementary-material"}), and by teratoma formation upon intramuscular injection of undifferentiated FD-iPSCs into NOD-SCID mice ([Fig. 1i](#F1){ref-type="fig"}). Genetic identity was confirmed by DNA fingerprinting analysis for microsatellite markers ([Suppl. Table 1](#SD1){ref-type="supplementary-material"}). The genetic defect was confirmed as a homozygous 2507+6T\>C mutation in the *IKBKAP* gene ([Fig. 1j](#F1){ref-type="fig"}) known to induce tissue specific skipping of exon 20. Gene expression analysis for *IKBKAP* revealed that FD-fibroblasts and FD-iPSCs express both the wild-type and mutant *IKBKAP* transcript, although the ratio of normal to mutant transcript was higher in FD-iPSCs compared with FD-fibroblasts ([Fig. 1k](#F1){ref-type="fig"}).

The pluripotent nature of iPSCs offers the opportunity for probing the tissue specificity of the *IKBKAP* splicing defect *in vitro*. FD- and control-iPSCs (2 clones each) were differentiated into five major tissues comprising all three embryonic germ layers. No reactivation of transgenes was observed in differentiated progeny ([Suppl. Fig. 2](#SD1){ref-type="supplementary-material"}). Following directed differentiation towards CNS[@R14], PNS[@R15], hematopoietic[@R16], endothelial[@R17], and endodermal[@R18] precursors, iPSC derivatives were further enriched via prospective isolation using lineage specific surface markers ([Fig. 2a-f](#F2){ref-type="fig"}). Early neural differentiation was characterized by the formation of neural rosette structures in both FD- and control-iPSCs ([Suppl. Fig. 4](#SD1){ref-type="supplementary-material"}). No major differences were observed in the efficiency of differentiation towards any of the five lineages comparing FD- versus control-iPSCs (data not shown). However, marked differences were observed for the ratio of normal:mutant transcript among the five FD-iPSCs derived tissues (**insets**, [Fig. 2a-f](#F2){ref-type="fig"}). The mutant transcript predominated particularly in CXCR4+ purified endodermal precursors (Sox17+) and, to a lesser extent, in neural crest precursors ([Fig. 2g](#F2){ref-type="fig"}). The disease symptoms in FD are thought to be caused by loss of sufficient levels of normal *IKBKAP* transcript. Therefore we next performed qRT-PCR analysis determining absolute levels of normal spliced *IKBKAP* transcript in each of the five FD- or control-iPSC derived cell populations ([Fig. 2h](#F2){ref-type="fig"}). These data revealed particularly low levels of normal *IKBKAP* transcript in FD-iPSC derived neural crest precursors *in vitro* compatible with the tissue specific human pathology observed in FD patients. High levels of mutant *IKBKAP* expression in endodermal precursors are of interest in view of the debilitating gastrointestinal problems observed in FD; though such symptoms are thought to be a consequence of a primary defect in the peripheral nervous system.

Directed differentiation of patient-specific iPSCs towards neural crest lineages, the primary tissue affected in FD, enables modeling functional aspects of pathogenesis *in vitro*. Neuropathological studies have demonstrated a dramatic depletion of autonomic and sensory neurons in FD patients. However, the cause for peripheral neuron loss in FD remains unclear, and there are currently no mouse models that faithfully replicate the disease. Mouse modeling in other neural crest disorders has identified a number of potential disease mechanisms such as impaired neural precursor cell migration in Hirschsprungs' disease[@R19] or degeneration of established neural crest tissues in Treacher Collins syndrome[@R20]. We explored the involvement of candidate disease mechanisms in FD by performing comparative transcriptome analysis of FACS purified FD-iPSC versus control-iPSC derived neural crest precursors ([Fig. 3a](#F3){ref-type="fig"}, [Suppl. Table 2](#SD1){ref-type="supplementary-material"}; raw data of microarray data available at GEO <http://www.ncbi.nlm.nih.gov/geo/> accession number: GSE17043. Among 48,000 probe sets, 35 transcripts were significantly increased and 54 transcripts decreased in FD-iPSC versus control iPSC or hESC derived neural crest precursors (fold-change ≥ 2 fold; corrected p-value of 0.05). Differential expression of key transcripts from the microarray study was confirmed by qPCR analysis for neural crest precursors of both FD-iPSC clones ([Suppl. Fig. 5](#SD1){ref-type="supplementary-material"}). Importantly, among the 20 most decreased transcripts in FD neural crest precursors were many genes involved in peripheral neurogenesis and neuronal differentiation. Examples include *SLC17A6 (VGLUT2)* expressed in sensory neurons, the neuronal intermediate filaments *MAP4* and *INA*, and *STMN2* (*SCG-10*; a known marker of autonomic neurons[@R21]). Of particular interest were the significant differences in *ASCL1* of *(MASH1)* expression between FD- and control-iPSC given the essential role of Mash1 for the development of autonomic neurons during mouse development[@R21]. Differential expression of *MASH1* was further confirmed at the protein level by quantifying the percentages of MASH1-immunoreactive cells ([Fig. 3b](#F3){ref-type="fig"}). The marked differences in neurogenesis were also reflected by a reduction in the percentage of spontaneously differentiating Tuj1+ neurons in FD-iPSC derived neural crest precursor cultures ([Fig. 3c](#F3){ref-type="fig"}). Peripheral neurogenesis was not completely blocked, as FD-iPSC derived Brn3A+/Peripherin+ neurons were observed upon further in vitro differentiation (**inset** of [Fig. 3c](#F3){ref-type="fig"}). These data indicate a defect in the propensity of FD-iPSC derived neural crest precursors to undergo neuronal differentiation. Previous studies in *IKBKAP* depleted or patient-specific fibroblasts indicated that reduced levels of normal *IKBKAP* are associated with defects in cell migration[@R9],[@R22]. Using a wound healing ("scratch") assay we observed a significant decrease in the migration of FD-iPSC versus control-iPSC derived neural crest precursors ([Fig. 3d](#F3){ref-type="fig"}). FD-iPSC derived neural crest precursors also showed a reduction in the number of Paxillin+ focal adhesions critical for cell spreading and migration ([Fig. 3e](#F3){ref-type="fig"}).

Our study reveals defects in *IKBKAP* splicing, neurogenesis, and migration of FD-iPSC derived neural crest precursors. Results were validated in multiple independent FD-iPSC clones (see [Suppl. Fig. 6](#SD1){ref-type="supplementary-material"}) and compared to both non-affected control-iPSC and control hESC cultures. These data demonstrate that FD-iPSC derived neural crest precursors represent a powerful model system to probe disease pathogenesis, though larger sets of FD-iPSC lines may be useful to further validate disease phenotype.

Another key promise of human iPSC research is the use of patient-specific cells in drug discovery. Our study has demonstrated three easily quantifiable parameters of the disease state: a defect in *IKBKAP* splicing, decreased rate of neurogenesis, and reduced migration in FD-iPSC derived neural crest precursors. We next tested whether exposure to candidate drugs can impact any of these three parameters. The plant hormone kinetin was previously shown to reduce levels of the mutant *IKBKAP* splice form in FD-derived lymphoblast cell lines[@R12]. Epigallocatechin Gallate (ECGC) and tocotrienol have also been reported to affect splicing and absolute levels of *IKBKAP* [@R23],[@R24]. Exposure of FD-iPSC derived neural crest precursors to kinetin resulted in a dramatic reduction of the mutant *IKBKAP* splice form ([Fig. 4a](#F4){ref-type="fig"}). In contrast, no significant improvements in *IKBKAP* splicing were observed upon ECGC or tocotrienol exposure ([Suppl. Fig. 7](#SD1){ref-type="supplementary-material"}). The kinetin-mediated decrease in mutant *IKBKAP* was associated with an increase in normal *IKBKAP* levels and the ratio of normal:mutant transcript ([Fig. 4b](#F4){ref-type="fig"}). No significant increase in normal *IKBKAP* transcript levels were observed upon kinetin treatment of neural crest precursors derived from control iPSCs ([Suppl. Fig. 8](#SD1){ref-type="supplementary-material"}). While short-term (1 day or 5 day) kinetin treatment of FD-iPSC derived neural crest precursors had dramatic effects on *IKBKAP* splicing, it did not result in a significant increase in the expression of neurogenic markers or improve migration behavior. ([Suppl. Fig. 9](#SD1){ref-type="supplementary-material"} & [Suppl. Fig. 10](#SD1){ref-type="supplementary-material"}). We next tested the impact of continuous (28 day) kinetin treatment of FD-iPSCs starting at the pluripotent stage 1 day prior to differentiation ([Suppl. Fig. 11](#SD1){ref-type="supplementary-material"}). Importantly, continuous kinetin treatment induced a significant increase in the percentage of differentiating neurons and in the expression of key peripheral neuron markers such as *MASH1* and *SCG-10* at the neural crest precursor stage ([Fig. 4c,d](#F4){ref-type="fig"}). No significant increase was observed in FD-iPSC neural crest precursor cell migration ([Fig. 4e](#F4){ref-type="fig"}) suggesting incomplete restoration of disease phenotype. These data demonstrate the feasibility of exploring disease mechanism and action of candidate drugs in FD-iPSCs. While future studies will be required to define the developmental windows of kinetin action in greater detail, our data indicate that early stage long-term treatment may be particularly beneficial in FD patients.

Since the initial reports on human iPSC isolation[@R1]-[@R3], a number of patient-specific iPSC lines have been developed[@R4]-[@R7]. Modeling human disease in iPSCs has remained challenging due to difficulties in directing iPSC fate and identifying disease related behaviors. Previous reports have demonstrated the derivation of patient specific motoneurons and dopamine neurons as an initial step in modeling ALS, SMA and Parkinson's disease respectively[@R4],[@R5],[@R7]. While the study using SMA-iPSCs reported a potentially disease-related loss of cholinergic neurons[@R5], the other studies did not observe[@R7] or not report[@R4] any disease related phenotypes. Interestingly, both SMA and FD are early onset disorders suggesting that iPSC technology may be particularly suited to model developmental disorders. Here we extend the approach to modeling disease in the neural crest lineage and provide clear evidence of disease related behaviors in FD-iPSCs. While FD is a rare genetic disorder with an incidence of 1/3600 live birth among the Ashkenazi Jewish population (\~ 600 registered patients world-wide[@R25]), it provides a platform to demonstrate the potential of iPSC technology for exploring disease mechanism in a human genetic disorder. Studying aberrant tissue specific *IKBKAP* splicing in iPSCs will be particularly attractive given the pluripotent nature and unlimited number of cells available for mechanistic studies and for high-throughput drug discovery. Our data on defects in neurogenic propensity and migration of FD-iPSC derived neural crest precursors provide novel insights into disease pathogenesis and suggest alternative functional assays for the identification and validation of candidate drugs. Finally, kinetin treatment illustrates the potential of iPSC technology for modeling therapeutic action in human neural disease *in vitro* using patient specific cells.

Methods Summary {#S1}
===============

iPSC generation and differentiation {#S2}
-----------------------------------

FD- and control fibroblasts were obtained from Coriell and reprogrammed towards iPSCs using a lentiviral four factor protocol (Oct4, Sox2, Klf4 and Myc) described recently[@R13]. Undifferentiated hESCs and iPSC lines were maintained on mitotically inactivated MEFs in serum-replacement medium in the presence of 4 ng/ml FGF2[@R15]. For neural induction, hESCs were plated on a confluent layer of irradiated stromal cells (MS-5) as described previously[@R15],[@R26]. After 3-4 weeks of differentiation hESC progeny was triturated into single cells following Accutase dissociation (Innovative cell technologies) and labeled with antibodies for flow cytometry. Protocols for directed differentiation into all the other individual lineages are described in the **Full Methods** section.

Karyotype analysis and Teratoma formation {#S3}
-----------------------------------------

Standard G-banding analysis was performed by MSKCC molecular cytogenetics core laboratory as described previously[@R27]. For teratoma formation FD-iPSCs were injected into the hindlimb muscle of *NOD-SCID IL2Rgc* null mice (Jackson Laboratory) and analyzed histologically 4-6 weeks after injection. Animal studies were approved by MSKCC Institutional Animal Care and Use Committee.

Molecular analyses {#S4}
------------------

Total RNA was extracted using the RNeasy kit and DNAse I treatment (Qiagen) and reverse transcribed (Superscript, Invitrogen). Primer sequences, cycle numbers, and annealing temperatures ([Suppl. Table 3](#SD1){ref-type="supplementary-material"}) for *IKBKAP* correspond to those used by others[@R12] and quantification of PCR bands was performed using ImageJ software (NIH) and ratio of normal:mutant transcript was determined. Quantitaive RT-PCR analysis was performed as described previously[@R28]. Gene expression microarray analysis was carried out by the SKI genomics core laboratory using the human Illumina-12 and Illumina-6 platforms. Bisulfite sequencing analysis of Nanog promoter was performed according to[@R3].

Immunocytochemistry {#S5}
-------------------

Cells were fixed in 4% paraformaldehyde, permeabilized with Triton-X100 containing buffer and stained with primary antibodies (list of antibodies provided in the **Full Methods** section). Appropriate fluorescent labeled secondary antibodies (Molecular Probes) and DAPI counter-staining was used for visualization.
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![Establishment of FD-iPSCs from patient fibroblasts\
(**a-b**) FD patient fibroblasts (**a**) were converted into FD-iPSCs (**b, c**) following lentiviral transduction with OCT4, SOX2, KLF4, and cMYC. **d**, Nanog protein expression in FD-iPSC line. **e**, Flow-cytometry analysis of FD-iPSCs for pluripotent surface markers. **f**, Karyotype analysis of FD-iPSCs. **g**, Bisulfite sequencing analysis of NANOG promoter in FD-fibroblast and FD-iPSC clones. **h**, Global gene expression patterns were compared among FD-fibroblast, FD-iPSCs and human ESCs. **i**, Teratoma from FD-iPSCs showed three germ-layer differentiation as illustrated by the presence of endodermal epithelia expressing β-catenin, Pax6+ neuroectodermal precursors and mesodermal collagen+ cells. **j**, Sequencing result showed the 2507+6T\>C mutation of IKBKAP in FD-iPSC. **k**, Analysis of IKBKAP RT-PCR products in mRNA derived from normal and FD-specific fibroblasts and pluripotent stem cells. All scale bars correspond to 50μm.](nihms-135763-f0001){#F1}

![FD-iPSC derived cell lineages model the tissue specificity of FD IKBKAP splicing defect\
**a**, Undifferentiated iPSCs were defined by NANOG expression and quantitative analysis of TRA1-81. **b-f**, FD-iPSCs were directed towards specific lineages and purified by flow-cytometric sorting for appropriate surface markers. The cell types analyzed included AP2+ neural crest precursors purified based on HNK1+ expression (**b**), FACS purified Forse1+ neural rosette cells (Pax6+) (**c**), hematopoietic cells that were harvested from colony forming unit culture and sorted with CD45 marker (**d**), FACS isolated CD144+ (VE-cadherin) endothelial cells (CD105+) from blast colony culture (**e**), FACS isolated CXCR4+ endodermal precursors (Sox17+) from ActivinA-induced differentiation culture (**f**). IKBKAP RT-PCR products of FACS purified lineages (bottom panel). The ratio of normal:mutant splicing **(g)** and expression of normal IKBKAP transcript **(h)** are shown. *n* = 3 -- 6; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001. All values are mean ± s.d. All scale bars correspond to 50μm.](nihms-135763-f0002){#F2}

![Molecular and functional characterization of FD-iPSC derived neural crest precursor cells\
**a**, List of the unselected top increased (blue) and top decreased (red) genes comparing FD-iPSC versus \[C14 and H9\] derived neural crest cells as assessed by microarray analysis. **b-c**, Representative images and quantifications of MASH1 (**b**) and Tuj1 (**c**) expression in spontaneously differentiated neural crest cells derived from FD-iPSC and C14-iPSC. *n* = 4; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001. **c, inset**, Representative image of putative sensory neuron progeny (Brn3a+/Periperin+) from FD-iPSC derived neural crest cells. **d-e**, Representative images of wound healing assay (fixed at 48 hrs after scratching) and paxillin staining (fixed at 1.5 hrs after plating) of FD-iPSC and C14-iPSC derived neural crest cells. *n* = 4; \*, p \< 0.05. Quantification of paxillin staining was performed by counting the number of Paxillin puncta marking focal adhesion complex. All values are mean ± s. d. All scale bars correspond to 50μm.](nihms-135763-f0003){#F3}

![Validating kinetin as a candidate compound for treating FD-iPSC derived neural crest cells\
**a**, Gel image of RT-PCR products for IKBKAP splicing rescued by kinetin treatment in control and FD-iPSC derived neural crest. **b**, Quantification of band intensity of FD-iPSC derived neural crest cells normalized by GAPDH and the ratio of normal and mutant spliced IKBKAP transcripts. *n* = 5; \*, p \< 0.05; \*\*\*, *P* \< 0.001. **c-d**, MASH1 (**c**) and Tuj1 (**d**) expression in neuronal differentiation with kinetin treated neural crest cells derived from FD-iPSC . *n* = 4; \*\*\*, *P* \< 0.001. (E-F) Results of wound healing assay (**e**) and paxillin staining (**f**) of kinetin treated FD-iPSC derived neural crest cells. *n* = 4 - 6; \*\*\*, *P* \< 0.001. All values are mean ± s. d.](nihms-135763-f0004){#F4}
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